Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 29;13(6):1327.
doi: 10.3390/biomedicines13061327.

A Narrative Review of Current and Investigational Therapies in Hypertrophic Cardiomyopathy

Ian Ogurek  1 , Randeep Gill  1 , Vasiliki Tasouli-Drakou  1 , Ronnie Joseph  1 , Arbab Khalid  1 , Nazanin Houshmand  2 , Tahir Tak  2
Affiliations
Review

A Narrative Review of Current and Investigational Therapies in Hypertrophic Cardiomyopathy

Ian Ogurek et al. Biomedicines. .

Abstract

Hypertrophic cardiomyopathy is the most prevalent inherited cardiac condition, distinguished by an autosomal dominant inheritance pattern. Diagnosis can be achieved through echocardiography, cardiac magnetic resonance imaging, and genetic testing. Recently, significant advancements have occurred in pharmacological and invasive therapies that are transforming the management of hypertrophic cardiomyopathy, including the introduction of cardiac myosin inhibitors, radiofrequency ablation, and gene editing. Additional trials are being conducted on investigational therapies, with the results anticipated in the near future. This review aims to provide a concise overview of both currently approved and investigational treatments for hypertrophic cardiomyopathy.

Keywords: advanced therapies; hypertrophic cardiomyopathy; procedural interventions.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Outflow diagram highlighting the steps for diagnosing and treating HCM based on ACC guidelines. HCM: hypertrophic cardiomyopathy [4].
Figure 2
Figure 2
Types of therapies for HCM.
See this image and copyright information in PMC

References

    1. Antunes M.d.O., Scudeler T.L. Hypertrophic Cardiomyopathy. Int. J. Cardiol. Heart Vasc. 2020;27:100503. doi: 10.1016/j.ijcha.2020.100503. - DOI - PMC - PubMed
    1. Ho C.Y., Mealiffe M.E., Bach R.G., Bhattacharya M., Choudhury L., Edelberg J.M., Hegde S.M., Jacoby D., Lakdawala N.K., Lester S.J., et al. Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic Cardiomyopathy. J. Am. Coll. Cardiol. 2020;75:2649–2660. doi: 10.1016/j.jacc.2020.03.064. - DOI - PubMed
    1. Massera D., Sherrid M.V., Maron M.S., Rowin E.J., Maron B.J. How Common Is Hypertrophic Cardiomyopathy… Really?: Disease Prevalence Revisited 27 Years After CARDIA. Int. J. Cardiol. 2023;382:64–67. doi: 10.1016/j.ijcard.2023.04.005. - DOI - PubMed
    1. Maron B.J., Desai M.Y., Nishimura R.A., Spirito P., Rakowski H., Towbin J.A., Rowin E.J., Maron M.S., Sherrid M.V. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2022;79:372–389. doi: 10.1016/j.jacc.2021.12.002. - DOI - PubMed
    1. Braunwald E. Hypertrophic Cardiomyopathy: A Brief Overview. Am. J. Cardiol. 2024;212S:S1–S3. doi: 10.1016/j.amjcard.2023.10.075. - DOI - PubMed

LinkOut - more resources